首页> 外国专利> THYROTROPIN RECEPTOR PREPARATIONS, BINDING REGIONS THEREOF, ANTIBODY AND HORMONY INTERACTIONS THEREFOR AND APPLICATIONS THEREOF

THYROTROPIN RECEPTOR PREPARATIONS, BINDING REGIONS THEREOF, ANTIBODY AND HORMONY INTERACTIONS THEREFOR AND APPLICATIONS THEREOF

机译:甲状腺素受体的制备,其结合区域,抗体和激素的相互作用及其应用

摘要

A mutated TSHR preparation which includes at least one point mutation characterized in that at least amino acid Arg at a position corresponding to amino acid 255 of a full length human TSHR has been mutated to a different amino acid residue in said mutated TSHR preparation, whereby said mutated TSHR preparation differentially interacts with patient serum stimulating TSHR autoantibodies, patient serum blocking TSHR autoantibodies and TSH, in that (i) the stimulatory effect of patient serum stimulating TSHR autoantibodies interacting with the mutated TSHR preparation is substantially reduced or essentially abolished, when compared to the stimulatory effect of the patient serum stimulating TSHR autoantibodies interacting with a reference TSHR preparation which has an amino acid sequence corresponding to that of said mutated TSHR preparation with the exception that said mutation of Arg at a position corresponding to amino acid 255 of a full length human TSHR is not present in said reference TSHR preparation, (ii) the stimulatory effect of TSH when interacting with the mutated TSHR preparation is essentially unaffected, when compared to the stimulatory effect of TSH interacting with said reference TSHR preparation, and (iii) the blocking effect of patient serum blocking TSHR autoantibodies interacting with the mutated TSHR preparation is essentially unaffected or increased, when compared to the blocking effect of the patient serum blocking TSHR autoantibodies interacting with said reference TSHR preparation, whereby said mutated TSHR preparation is effective in the differential screening and identification of patient serum stimulating TSHR autoantibodies, patient serum blocking TSHR autoantibodies and TSH in a sample of body fluid being screened.
机译:一种包括至少一个点突变的突变的TSHR制剂,其特征在于,在所述突变的TSHR制剂中,对应于全长人TSHR的氨基酸255的位置上的至少氨基酸Arg已被突变为不同的氨基酸残基,从而所述突变的TSHR制剂与刺激TSHR自身抗体的血清,阻断TSHR自身抗体和TSH的患者血清的相互作用不同,因为(i)与刺激TSHR自身抗体与参考TSHR制剂相互作用的患者血清的刺激作用,所述参考TSHR制剂具有与所述突变的TSHR制剂的氨基酸序列相对应的氨基酸序列,不同之处在于所述Arg突变在与全长氨基酸255相对应的位置处该参考文献中不存在人类TSHR e)TSHR制剂,(ii)与TSH与所述参考TSHR制剂相互作用的刺激作用相比,(ii)TSH与突变TSHR制剂相互作用时的TSH刺激作用基本上不受影响,以及(iii)患者血清阻断TSHR的阻断作用与患者血清阻断TSHR自身抗体与所述参考TSHR制剂相互作用的阻断作用相比,与突变TSHR制剂相互作用的自身抗体基本上不受影响或增加,由此所述突变TSHR制剂在差异筛选和鉴定患者血清刺激中有效TSHR自身抗体,患者血清封闭性TSHR自身抗体和体液样本中的TSH。

著录项

  • 公开/公告号AT509952T

    专利类型

  • 公开/公告日2011-06-15

    原文格式PDF

  • 申请/专利权人 RSR LIMITED;

    申请/专利号AT20050767857T

  • 申请日2005-08-03

  • 分类号C07K14/72;A61P5/06;C12N15/12;G01N33/53;G01N33/564;

  • 国家 AT

  • 入库时间 2022-08-21 18:03:16

相似文献

  • 专利
  • 外文文献
  • 中文文献
获取专利

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号